Date: 2017-09-06
Type of information: Clinical research agreement
Compound: Tedopi®
Company: OSE Immunotherapeutics (France) GERCOR (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: clinical research
Action mechanism:
- immunotherapy product. Tedopi® (OSE2101) targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains ten optimized epitopes, or “neoepitopes”, designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. These five tumor antigens (HER-2/neu, p53, CEA, MAGE-2 and MAGE-3) are expressed in various tumors related to poor prognosis and even poorer when associated.
- Since February 2013, OSE2101 has been granted orphan drug status by the FDA for the treatment of NSCLC in patients expressing HLA-A2.
Disease: locally advanced or metastatic pancreatic cancer
Details:
- • On September 6, 2017, OSE Immunotherapeutics announced an agreement with GERCOR, an independent non-profit French network of cancer specialists, to study Tedopi® in locally advanced or metastatic pancreatic cancer. GERCOR is finalizing the design of this Phase 2 trial of maintenance therapy with Tedopi® alone or combined with a PD-1 checkpoint inhibitor versus Folfiri*, in patients with stable disease after 4 months of standard chemotherapy with Folforinox (combination chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin). Professor Christophe Louvet, President of GERCOR, added: “Tedopi®’s effects on the tumor microenvironment could make checkpoint inhibitors relevant for a larger percentage of patients(...).”
Financial terms:
Latest news:
Is general: Yes
